Immunocore Secures $130 Million Series B Financing

Led by General Atlantic, funding will expand novel scientific platform and advance proprietary pipeline of ImmTAX™ molecules into the clinic

(Oxfordshire, UK and Conshohocken, Pa. and Rockville, Md., US, 2 March 2020) Immunocore, a pioneering, clinical-stage T cell receptor biotechnology company working to develop and commercialize a new generation of transformative medicines to address unmet needs in cancer, infection and autoimmune disease, today announced the completion of its Series B private financing round, generating more than $130 million.